BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36528061)

  • 1. Difluoromethyl-1,3,4-oxadiazoles are slow-binding substrate analog inhibitors of histone deacetylase 6 with unprecedented isotype selectivity.
    Cellupica E; Caprini G; Cordella P; Cukier C; Fossati G; Marchini M; Rocchio I; Sandrone G; Vanoni MA; Vergani B; Źrubek K; Stevenazzi A; Steinkühler C
    J Biol Chem; 2023 Jan; 299(1):102800. PubMed ID: 36528061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Difluoromethyl-1,3,4-oxadiazoles Are Selective, Mechanism-Based, and Essentially Irreversible Inhibitors of Histone Deacetylase
    König B; Watson PR; Reßing N; Cragin AD; Schäker-Hübner L; Christianson DW; Hansen FK
    J Med Chem; 2023 Oct; 66(19):13821-13837. PubMed ID: 37782298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selectivity of Hydroxamate- and Difluoromethyloxadiazole-Based Inhibitors of Histone Deacetylase 6 In Vitro and in Cells.
    Ptacek J; Snajdr I; Schimer J; Kutil Z; Mikesova J; Baranova P; Havlinova B; Tueckmantel W; Majer P; Kozikowski A; Barinka C
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective and Bioavailable HDAC6 2-(Difluoromethyl)-1,3,4-oxadiazole Substrate Inhibitors and Modeling of Their Bioactivation Mechanism.
    Ripa L; Sandmark J; Hughes G; Shamovsky I; Gunnarsson A; Johansson J; Llinas A; Collins M; Jung B; Novén A; Pemberton N; Mogemark M; Xiong Y; Li Q; Tångefjord S; Ek M; Åstrand A
    J Med Chem; 2023 Oct; 66(20):14188-14207. PubMed ID: 37797307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases.
    Christianson DW
    Acc Chem Res; 2024 Apr; 57(8):1135-1148. PubMed ID: 38530703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Mechanistic View of the Hydrolysis of Oxadiazole-Based Inhibitors by Histone Deacetylase 6 (HDAC6).
    Motlová L; Šnajdr I; Kutil Z; Andris E; Ptáček J; Novotná A; Nováková Z; Havlínová B; Tueckmantel W; Dráberová H; Majer P; Schutkowski M; Kozikowski A; Rulíšek L; Bařinka C
    ACS Chem Biol; 2023 Jul; 18(7):1594-1610. PubMed ID: 37392419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
    Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
    Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors.
    Liang YY; Zhang CM; Liu ZP
    Expert Opin Ther Pat; 2018 Aug; 28(8):647-651. PubMed ID: 30073889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group.
    Lobera M; Madauss KP; Pohlhaus DT; Wright QG; Trocha M; Schmidt DR; Baloglu E; Trump RP; Head MS; Hofmann GA; Murray-Thompson M; Schwartz B; Chakravorty S; Wu Z; Mander PK; Kruidenier L; Reid RA; Burkhart W; Turunen BJ; Rong JX; Wagner C; Moyer MB; Wells C; Hong X; Moore JT; Williams JD; Soler D; Ghosh S; Nolan MA
    Nat Chem Biol; 2013 May; 9(5):319-25. PubMed ID: 23524983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
    Negmeldin AT; Pflum MKH
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods for the expression, purification, and crystallization of histone deacetylase 6-inhibitor complexes.
    Osko JD; Christianson DW
    Methods Enzymol; 2019; 626():447-474. PubMed ID: 31606087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6.
    Porter NJ; Wagner FF; Christianson DW
    Biochemistry; 2018 Jul; 57(26):3916-3924. PubMed ID: 29775292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fragment-Based Drug Design of Selective HDAC6 Inhibitors.
    Ruzic D; Djokovic N; Nikolic K
    Methods Mol Biol; 2021; 2266():155-170. PubMed ID: 33759126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of novel N-benzyltriazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
    Kong SJ; Nam G; Boggu PR; Park GM; Kang JE; Park HJ; Jung YH
    Bioorg Med Chem; 2023 Feb; 79():117154. PubMed ID: 36645952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).
    He X; Li Z; Zhuo XT; Hui Z; Xie T; Ye XY
    Recent Pat Anticancer Drug Discov; 2020; 15(1):32-48. PubMed ID: 32065106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of the first non-hydroxamate selective HDAC6 degraders.
    Keuler T; König B; Bückreiß N; Kraft FB; König P; Schäker-Hübner L; Steinebach C; Bendas G; Gütschow M; Hansen FK
    Chem Commun (Camb); 2022 Oct; 58(79):11087-11090. PubMed ID: 36098075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
    Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
    Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
    Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
    Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
    Tavares MT; Kozikowski AP; Shen S
    Eur J Med Chem; 2021 Jan; 209():112887. PubMed ID: 33035922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.